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Abstract 
The beneficial effects of n-3 long-chain polyunsaturated fatty acids, especially 
EPA and DHA, for human health are widely recognised. Intakes of these fatty 
acids in many parts of Europe fall far short of the recommended intake, especially 
in young people. The most robust evidence from human health studies 
demonstrating beneficial effects is that for cardiovascular disease. Other beneficial 
effects have been reported for inflammatory diseases such as rheumatoid arthritis, 
Crohn’s disease and ulcerative colitis, cognitive and visual development in pre-
term infants, and on various psychological/behavioural and psychiatric disorders. 
For European consumers fish is the main source of EPA and DHA, especially oily 
fish, and in particular farmed Atlantic salmon. With   evidence of a strong El Niño 
type event occurring in the Pacific currently (2015/16), fish stock biomasses have 
drastically declined and permitted fishing heavily reduced. Subsequent fish oil 
shortages have resulted in increased substitution of fish oil with vegetable oil in 
feeds for farmed salmon. A significant fall in EPA and DHA in these fish and a 
reduction in intake by consumers are expected in the short term. Avoiding fish oil 
shortages causing reductions in EPA and DHA intake by consumers in the future 
may be possible through the production of DHA-rich algal biomass if the cost can 
be reduced. Genetically modified crops which might also be a source of these fatty 
acids are unlikely to be acceptable for salmon feeds in Europe in the near future. 
 
Practical applications 
 
If farmed Atlantic salmon is to continue to be an important source of EPA and 
DHA in European diets, especially those in the UK, consideration will have to be 
given to obtaining new sources of these fatty acids. It would be prudent to follow 
the development of cheaper forms of DHA-rich algal biomass for incorporation 
into salmon feeds. Any relaxation of the public’s objections to the use of 
genetically modified crops to produce ingredients for salmon feeds should be 
followed. It may present the opportunity to use, for example, genetically modified 
Camelina sativa as an alternative source. 
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1  Introduction 
The beneficial effects of n-3 long-chain polyunsaturated fatty acids (LC-PUFA), 
especially eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 
22:6n-3), on human health are widely recognised. There are over 2000 published 
reports, including epidemiological and randomised controlled trials, which 
generally show positive benefits (summarised briefly below). Furthermore, fish 
and fish oil have long been appreciated as almost unique sources of n-3 LC-PUFA 
to the human population [1,2]. The present paper presents an assessment of the 
implications that this has on the supply of these important nutrients, and discusses 
factors potentially influencing and limiting supply including the effects of an El 
Niño event (El Niño Southern Oscillation –ENSO).  
 
2  Importance of n-3 LC-PUFA in human health 
Evidence of the beneficial effects of dietary EPA and DHA on human health has 
been largely based on epidemiological studies and randomised controlled 
(intervention) trials, although laboratory studies investigating biochemical and 
molecular mechanisms have also provided mechanistic support to these in vivo 
approaches [3]. Many recommendations for EPA and DHA intakes have been 
produced by a large number of global and national health agencies and 
associations, and government bodies [4]. In their review of the recommended 
amounts of EPA plus DHA, Givens and Gibb [1] showed an average value of 450 
mg per day. 
Despite the very wide ranging studies on health effects of n-3 LC-PUFA, the most 
robust evidence demonstrating beneficial effects of dietary EPA and DHA remains 
that for cardiac and cardiovascular disease (CVD). Epidemiological studies, 
looking at n-3 LC-PUFA intake (fish/fish oil) and/or status (blood/tissue fatty acid 
compositions) consistently show protective effects, reducing the risk of developing 
CVD [5]. Randomised controlled trials, normally designed for patients with some 
disease already (i.e. in at-risk patients), have also been generally positive and show 
that patients benefit from dietary n-3 LC-PUFA therapy [6,7]. Until recently, meta-
analyses were also largely positive [8,9] although there have been some recent 
studies questioning the efficacy of n-3 PUFA supplements [10,11]. The 
biochemical mechanisms underlying the beneficial effects of n-3 LC-PUFA are 
primarily based on their lowering of known risk factors for CVD and effects on 
platelet function [12]. Based on their effects on CVD, many health agencies 
worldwide recommend up to 500 mg/d of EPA and DHA for reducing CVD risk or 
1 g/d for secondary prevention in existing CVD patients, with a dietary strategy for 
achieving 500 mg/d being to consume 2 fish meals/week with at least one of oily 
fish [13-16]. 
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   There is evidence for beneficial effects of n-3 LC-PUFA in many other 
conditions and pathologies although it tends to be less robust than that for CVD. 
With inflammatory diseases the best evidence is for rheumatoid arthritis [17], 
although doses of n-3 LC-PUFA required to gain benefit are around 3g per day, 
and there is also increasing evidence in Inflammatory Bowel Disease such as 
Crohn’s disease and ulcerative colitis [18]. It should be noted that vascular 
diseases often have an inflammatory beginning. Supporting human studies, there is 
a very large body of research into the mechanisms of action of n-3 LC-PUFA on 
inflammatory pathways [19-22]. Regarding neurological function, there is robust 
evidence that DHA supplements have positive beneficial outcomes on cognitive 
and visual development in pre-term infants [23].  There have also been several 
reports of potential beneficial effects of dietary DHA supplementation in various 
psychological/behavioural/psychiatric disorders including attention deficit 
hyperactivity disorder and it is becoming recognized that n-3 LC-PUFA may help 
to prevent/mitigate various pathological conditions associated with the normal 
aging process including dementia/Alzheimer’s disease [24,25]. There is limited 
epidemiological evidence indicating that consumption of oily fish or taking n-3 
LC-PUFA supplements may have a protective effect (i.e. decreasing risk) in colo-
rectal, breast and prostate cancers [26]. However, further evidence is difficult to 
obtain as randomised, controlled trials similar to those carried out in CVD are not 
possible in cancer, but there are studies indicating some beneficial effects of n-3 
LC-PUFA supplementation in chemotherapy [27].  
Although the overwhelming weight of evidence supports beneficial effects of 
dietary n-3 LC-PUFA there has been some negative reporting such as that on 
prostate cancer [28,29] that impacted on sales of fish oil capsules for direct human 
consumption [30]. However, a very recent meta-analysis across approximately 20 
studies did not support an association between n-3 LC-PUFA and prostate cancer 
[31]. Other meta-analyses studies have questioned the efficacy of n-3 supplements 
for the secondary prevention of cardiovascular disease [11,32,33]. However, these 
meta-analyses studies have been hotly debated and disputed particularly over the 
influence of one or two null studies that can skew the data [34]. In addition, recent 
work has suggested that, with concentrated n-3 ethyl ester supplements, the 
method of delivery has an impact and that these should be taken with a fatty meal 
in order to stimulate a full digestive response and ensure proper digestion and 
maximum bioavailability of the EPA and DHA [35].  
3  Sources of n-3 LC-PUFA and intake recommendations. 
Studies of intakes of the n-3 LC-PUFA, in particular EPA and DHA, in parts of the 
European population show a wide range from under 100 mg per day in females 18 
to 39 years of age and children in Belgium, to 590 mg per day for adults in 
Northern Europe [1]. Taking the UK as an example, adult intake was 244 mg per 
day, with 199 mg per day from fish, 37 mg from meat and 9 mg from eggs. 
Ruminant animals grazing grass (dairy cows, beef and sheep) can convert a small 
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proportion of the α-linolenic acid (18:3n-3) they consume to EPA and DHA 
[36,37]. Grass has only a low lipid content, but this has a high proportion of α-
linolenic acid. Unsaturated lipids are extensively bio-hydrogenated in the rumen, 
but small (trace) amounts of α-linolenic acid are believed to be converted to EPA 
and DHA. Grass fed beef and dairy cows have been found to have traces of EPA 
and DHA in the meat and milk respectively. The contribution of land-animal meat 
consumed by humans to EPA and DHA intake was primarily due to 16 mg from 
poultry [38] compared with 27 mg estimated by [1].  There is evidence of limited 
production of these fatty acids in poultry from α-linolenic acid, which is present in 
grasses, see above, and some vegetable oils including rapeseed oil [39]. They 
showed that a variety of sources of α-linolenic acid included in the diet resulted in 
both EPA and DHA being present in intramuscular lipids of broiler meat. Most 
poultry reared in Europe have very little fishmeal (which contains fish lipids) in 
their feed nowadays and only from one to 10 days of age, so that the deposition of 
n-3 LC-PUFA from this source would be minimal. So the conversion from α-
linolenic acid in full-fat rapeseed meal [39] which many poultry receive may, to  a 
limited extent, offset the reduction of EPA and DHA from fish products in poultry 
(broiler) feeds which has occurred in the past five years.  
The consumption of poultry meat in the UK has risen to around 469 
g/person/week, according to the National Diet and Nutrition Survey, 2014 [40]. 
The only recent study of the fat composition of poultry obtained from retailers is 
that from [38]. Based on cooked chickens obtained from supermarkets that study 
showed a content of EPA plus DHA of approximately 23 mg and 26 mg/100 g 
respectively in skinless breast and leg meat. Taking 24 mg/100 g as a 
representative content of EPA plus DHA, this equates to 16 mg/person/day from 
poultry meat consumed. 
Of concern is that the intake of EPA and DHA from fish, poultry and other land-
animal products is inadequate. Surveys show that young people eat less fish than 
older people and so are more dependent on land animal products as a source of 
these fatty acids. 
Although there has been an increase in the production of refined and deodorised 
fish oil going into nutraceuticals – such as fish oil capsules and foodstuffs 
supplemented with n-3 LC-PUFA, the majority of  young people are not believed 
to consume significant quantities, if any [1]. Clearly there is a need to increase 
intake and fish products are the most effective way. Of these, salmon is the most 
important as the largest contributor of these fatty acids in the diet of many 
Europeans (especially in Ireland, Belgium and the UK). Although the average 
intake of n-3 LC-PUFA from seafood in Europe was 350 mg per day in 2010 [41] 
many individuals would get far less, particularly in those countries with low per 
capita intake of seafood. According to [42], the main oily fish species consumed 
on an annual basis were salmon 1.72 kg, herring 1.18 kg, mackerel 0.87 kg and 
sardine 0.71 kg. Salmon, and particularly farmed salmon, which accounts for 98 % 
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of total salmon, only 2% being wild [42], was the major oily fish species 
consumed. However, for many European countries outside Scandinavia and the 
Mediterranean areas, little oily fish is consumed except salmon. Clearly there is a 
need to increase fish intake, but efforts to do so have not been very successful in  
young people (18-24 years old)(1). So for many consumers on low intakes of fish 
where the majority is salmon they are very dependent on the contribution of that 
fish. With the prospects of an El Niño reducing supplies of fish oil how might this 
affect the intakes of n-3 LC-PUFA from farmed salmon? 
4  Could an El Niño event be developing? 
The US National Oceanographic and Atmospheric Administration (NOAA) uses 
the Oceanic Niño Index (ONI) as the standard for identifying El Niño (warm) 
events in the tropical Pacific (Niño 3.4 region). Events are defined as five 
consecutive overlapping three-month periods at or above the + 0.5 anomaly for 
warm events. They are further classified as weak (0.5 to 0.9 C surface temperature 
(SST) anomaly), moderate (1.02 to 1.4), strong (1.5 to 1.9) and very strong (over 
2.0) [43]. 
According to a recent report from NOAA the current El Niño has just been 
classified as strong, and possibly very strong, with the expectation that it might be 
one of the  largest to have occurred since 1950 [44]. 
In the areas of the Pacific most affected by the rising sea temperatures, the fishing 
grounds are normally some of the richest in the world. The Peruvian organisation 
IMARPE (Insituto del Mar del Peru), which undertakes exploratory fishing to 
assess fish stock biomass, suspends fishing during periods of El Niño to allow 
stocks to recover. The consequence of this is that production of both of fishmeal 
and fish oil is dramatically reduced at that time. This is reflected in fish oil 
production in Peru and Chile which between them produce around half the global 
production. The effect on the latter is shown in Figure 1. The global fish oil 
production figures were kindly supplied by the publication Oil World [45]. The 
arrows indicate El Niño years and strength. In the years of the very strong El Niño 
global fish oil production appeared to drop by over 15 %. In 2015, production had 
already fallen to just over 800 thousand tonnes, about 15 % down reflecting the 
current El Niño. 
During the period of El Niño when fishing is allowed, it becomes more difficult as, 
to try to avoid the warm water, forage fish such as anchovy and horse mackerel 
move close to shore or into deeper water [46]. The food supplies for the fish is 
reduced and, as a result, they become emaciated with higher mortality. As well as 
the dramatic reduction in fish catches the oil yield from the fish is reduced as a 
consequence.  
 
.  
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5. The consequences of an El Niño for the fish oil available for aquaculture 
Because fish oil use in nutraceuticals commands a higher price than other outlets, 
usage is unlikely to be reduced for that purpose and, therefore, virtually all of the 
fall in production of fish oil will be reflected in that which is available for 
aquaculture, and in particular salmon feeds. These feeds contain high levels of 
lipid – up to 40 % in grower feeds. It has been shown that the lipid composition of 
the diet is reflected in that of the fish, especially oily fish such as salmon and trout 
(salmonids) [47,48]. So any further reduction in the use of fish oil could lead to a 
reduction in n-3 LC-PUFA levels in the flesh of farmed salmon. 
6  Changes in the n-3 LC-PUFA content of the flesh of salmonids. 
A recent publication reported lipid contents and fatty acid compositions of salmon 
products obtained from major UK retailers in March 2013 [49]. Based on the data 
in [49] the average contents of lipid and its n-3 and n-6 PUFA compositions 
(expressed as % total fatty acids) in the salmon products have been calculated 
(Table 1). Some of the farmed salmon products had relatively high contents of 
18:1n-9, 18-2n-6 and 18:3n-3, characteristic of vegetable oils and these products 
also had lower percentages of EPA and DHA. In contrast, farmed salmon with 
high levels of 16:0 and 22:1 characteristic of fish oil had higher proportions of 
EPA and DHA. There was a clear correlation between the levels of fatty acid 
markers of vegetable oil and fish oil reflecting contents in feeds and the final 
proportions of n-3 LC-PUFA in the flesh.  
This confirmed earlier research where fish oil was replaced progressively with 
linseed oil that is rich in α-linolenic acid [50]. The authors pointed out that this 
fatty acid is a favoured substrate for β-oxidation in salmonids and mammals. It is 
not regarded as detrimental in diets for humans. In many human diets in Northern 
Europe the n-6:n-3 PUFA ratio is unbalanced and heavily in favour of n-6 PUFA 
(typically 15:1 or higher) [51]. The dietary ratio of n-6:n-3 PUFA is not directly 
associated with cardiovascular disease risk according to the OTILIP study [52], 
which showed it was the absolute amounts of dietary linoleic and α-linolenic acids 
that were of greatest relevance to the conversion of the latter to EPA and DHA. 
Although linseed oil is not generally used in salmonid feeds, the vegetable oil 
predominantly used, rapeseed oil, also contains α-linolenic acid. Levels of this 
fatty acid are not as high in rapeseed oil compared to linseed oil, and it also 
contains significant amounts of n-6 PUFA as reflected in the composition of the 
farmed salmon flesh. Nevertheless it will still provide sufficient α-linolenic acid at 
a reasonable n-6:n-3 PUFA ratio (~2:1) to allow production of the n-3 LC-PUFA, 
EPA and DHA. Due to this endogenous production, the total substitution of marine 
ingredients in the feed gives some production of EPA and DHA in salmon flesh 
[53]. Further evidence of the reduction in flesh content of EPA and DHA with 
reduced dietary levels has been found [54]. 
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7  Effect of reducing fish oil in salmon feeds from 12.5 to 5.0g/100g on the 
content of n-3 LC-PUFA in flesh. 
The largest producer of farmed salmon in Europe is Norway which also supplies 
the greatest amount into the European market. According to NOFIMA, the fish oil 
content of salmon feeds in Norway had fallen to 11 % in 2013 [55]. Recent price 
increases are likely to reduce this to below 10 %. To illustrate the consequences the 
effect of a reduction in fish oil content from 12.5 % to 5 %, the resultant EPA plus 
DHA content of flesh has been calculated (Table 2).  Based on the regressions 
given by [47] the relationship between the EPA and DHA in the diet and in the 
flesh was linear; the relationship gave correlation coefficients of 0.966 (p = 
0.0001) and 0.979 (p = 0.0013), respectively. Assuming that the total lipid content 
of the diet was 30 g/100 g, of which 23 g/100 g was fatty acids, the fish oil 
reduction in the diet would have reduced the EPA plus DHA in salmon flesh from 
2.5 to 1.3 g/100 g (Table 2). 
Taking the UK as an example of a population with low fish consumption, the 
average per capita daily intake of EPA plus DHA is 232 mg (see [1] and also 
section 3). Of this, 131 mg is from oily fish. Salmon provides around 2.5g/100g 
flesh based on feeds as used in 2013 (Table 2). The effect of reducing the dietary 
content of fish oil from 12.5% to 5% would reduce these fatty acids in salmon 
flesh from 2.5g to 1.3g/100g.  
For a meal size of 140 g (one meal per week) the reduction becomes 3.5 g to 1.8 g, 
that is 50 mg to 26 mg per day. The average intake of 232 mg per day would as a 
consequence be reduced to 208 mg. As the average intake of 232 mg is already 
below the intake recommended for maintaining health (450 mg) (see above) the 
reduction of per capita intake due to lower fish oil inclusion in diets for farmed 
salmon to 208mg/day  could in due course further compromise health. As El Niño 
events occur frequently (see Figure 1),they could jeopardise supplies of EPA plus 
DHA,and per capita intake, unless alternatives to fish oil as a source of n-3 LC-
PUFA become available.. 
 
8. Possible future sources of EPA and DHA for salmon feeds 
Progress is being made identifying the heritability and mechanisms of n-3 LC-
PUFA deposition in salmon flesh [56]. Selective breeding rather than gene 
manipulation of fish may be the more appropriate way of enabling these findings 
to be applied. Progress is also being made in achieving high-level accumulation of 
EPA and DHA in transgenic oilseed crops [57]. Already the plant used, Camelina 
sativa, has been cultivated on a field scale and it is currently undergoing feeding 
trials in salmon [58]. Although current consumer attitudes in Europe would act as a 
barrier to the use of feed ingredients derived from transgenic plants, it is likely that 
these crops will be will be grown outside Europe, and the n-3 LC-PUFA-rich oils 
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available for global aquaculture industries. This could pose a significant and 
serious challenge to European aquaculture until consumer attitudes towards genetic 
modification change. 
Algal products rich in oil have been produced for some time on a small scale, 
making them very expensive. In the future it may be possible using heterotrophic 
fermentation technology to scale-up production and bring down costs to a level 
that will make algal biomass suitable as an additional source of DHA (and possibly 
EPA) to fish oil. A DHA-rich algal biomass (AB) produced from Schizochytrium 
sp. has been tested in two recently published trials with Atlantic salmon posts-
smolts. In one trial the AB was added at 2.5 % or 5.2 % of the diet to replace 
herring oil and maintain EPA plus DHA content, increasing the proportion of DHA 
relative to EPA [59]. The AB used contained a 61 % fat, 29 % DHA but only 0.3 
% EPA in the oil. Diets were formulated with 48 g EPA plus DHA per kg oil. 
Growth of the fish, feed conversion and lipid content were similar and not affected 
by treatment. The EPA plus DHA contents of flesh were also not greatly affected 
by the treatment. It was found that the retention of these fatty acids from AB was 
improved albeit largely due to the replacement of more easily oxidised EPA by 
DHA that is less easily oxidised, as was fish quality (gaping). 
In a further trial with AB rich in DHA (composition not given) either 11% or 5.5% 
of this replaced 27% fish oil in the diet [60]. The fish oil was either sourced from 
the Northern or Southern hemispheres. That from the latter had a higher EPA: 
DHA ratio. Levels of these fatty acids were reduced with the AB containing diets, 
especially with the lower level. The AB treatments resulted in poorer growth and 
feed conversion. Although lipid content of the flesh was similar, the EPA and 
DHA content was significantly reduced by the AB treatments. In these treatments 
the sum of these fatty acids in dietary lipid was less than half that in the fish oil 
treatments. Nevertheless, flesh levels were not reduced proportionately; they were 
reduced by about 35%. This might reflect more efficient uptake from AB as in the 
former trial [59]. However, when dietary levels of the fatty acids are reduced 
markedly the efficiency of uptake tends to increase possibly explaining part of the 
improved efficiency noted in [60]. 9  Conclusions 
 There have been wide ranging studies of the health effects of n-3 LC-PUFA in 
humans. There is robust evidence demonstrating beneficial effects of dietary EPA 
and DHA for cardiac and cardiovascular disease. There is evidence, though less 
robust, for beneficial health effects in many other conditions, including 
inflammatory diseases such as rheumatoid arthritis, and intestinal conditions such 
as Crohn’s disease. Neurological functions, and cognitive functions in children, 
have been shown to improve with DHA supplementation of the diet. 
A number of government bodies and national health agencies have recommended 
an intake of EPA plus DHA averaging 450 mg/person/day. Yet intake in much of 
Europe is much less than this; for example, it is estimated in the UK that intake 
averages 232 mg/person/day – see section 7 and [1]. 
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It is now confirmed that the current El Niño in the Pacific has been classed as  
strong, and may be very strong. Global production of fish oil is already declining 
as a result of the detrimental effects of warmer than normal sea temperatures on 
stocks of forage fish off the South American coast. The reduction in supplies of 
fish oil globally, and price increases as a consequence, are expected to more than 
half its contribution of EPA and DHA in salmon feeds, salmon being a significant 
source of these fatty acids in the UK diet, for example. A reduction averaging 24 
mg EPA plus DHA/person/day as a consequence is estimated which would cause 
an average intake drop from 232 mg to 208 mg/person/day against the 
recommended daily amount of 450 mg, further exacerbating the shortfall. 
With aquaculture continuing to grow and fish oil supplies not increasing, and with 
dramatic drops in production each time an El Niño occurs, supplies of EPA and 
DHA for feeds will be put in jeopardy; new sources are urgently needed. 
Technology to produce DHA-rich algal biomass from heterotrophic algae has been 
developed using fermentation technology. If this process can be scaled up to 
reduce the price of production, it could provide the additional supply of DHA, and 
to a lesser extent EPA, that fish farming and especially salmon production urgently 
need. Although the technology for the production of EPA plus DHA from plants 
such as Camelina sativa is now relatively well advanced, the need to use genetic 
modification is likely to rule out such a crop from European aquaculture in the near 
future. 
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Table 1. The average lipid contents, n-3 PUFA and n-6 PUFA compositions, and 
proportions of EPA, docosapentaenoic acid (DPA) and DHA (expressed as g/100g 
total fatty acids) in salmon products sourced from UK retailers in spring 2013. 
 
 Mean SD 
Total lipid (g/100g) 11.7 3.4 
Ʃ n-3 21.2 4.7 
Ʃ n-6 11.6 3.9 
Ratio n-3:n-6 2.2 1.4 
20:5n-3 (EPA)   5.5 2.3 
22:5n-3 (DPA) 2.3 0.8 
22:6n-3 (DHA) 7.5 2.6 
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Table 2. The effect of reducing fish oil content of salmon diets from 12.5 to 5.0 g 
oil/100g feed on the calculated concentration of n-3 LC-PUFA in fish flesh1. 
Changes in fish oil in salmon diets  FA in diet² 
(g/100g 
feed) 
FA in diet 
(g/100g 
lipid) 
   FA in  
      flesh¹   
(g/100g flesh)    
Amount of EPA from 12.5g 
oil/100g feed 
2.28 6.61 1.2 
Amount of EPA from 5.0g 
oil/100g feed 
0.91 2.64 0.55 
    
Amount of DHA from 12.5g 
oil/100g feed 
0.96 2.78 1.3 
Amount of DHA from 5.0 g 
oil/100g feed 
0.39 1.13 0.73 
    
¹Using regression in Fig. 2 of [47] 
²Assuming dietary fish oil to be Peruvian produced from anchovy, horse mackerel, 
sardine and pilchard: EPA content, 18.2g/100g oil; DHA content, 7.7 g/100g oil 
[61]. Total fatty acids in diets with mixed vegetable and fish oils assumed to be 
85%; in salmon flesh 80% [53]. 
 
 
 
 
 
 
 
